Searched for
BIOCON BIOLOGICS NEWS
Syngene shares zoom 17% even as firm’s Q4 net profit drops 19% YoY. What's driving the surge?Syngene shares surged despite a 19% YoY decline in Q4FY26 net profit to Rs 148 crore, as earnings rebounded sharply from Rs 15 crore in the...- Stocks in news: Titan, Tata Steel, JSW Steel, Pidilite Industries, M&MMarkets saw a subdued session, continuing a mild correction after recent highs. Several companies are in focus today. Titan reported strong...
- Biocon shares surge 3% as subsidiary obtains USFDA approval for diabetes drugBiocon share price jumped after its subsidiary Biocon Biologics received USFDA approval for Kirsty, a rapid-acting insulin biosimilar. This...
- Biocon shares climb 1% on partnership with Civica to boost insulin aspart availability in the USBiocon Biologics has partnered with Civica to improve access to and affordability of insulin aspart in the U.S. Biocon will supply the insu...
- Biocon shares in focus after subsidiary launches biosimilar alternative to Stelara in the USBiocon Biologics has launched YESINTEK, a biosimilar to Stelara, in the United States for treating chronic autoimmune conditions, offering ...
- Stocks in news: ONGC, NTPC, SBI Life, Manappuram Finance, BioconNTPC along with its arm NTPC Green Energy signed multiple MoUs with Madhya Pradesh government to invest over Rs 2 lakh crore in the state.
- Stocks in news: Nestle, Vedanta, L&T, Motilal Oswal, Greenlam IndustriesShares of Nestle India, IndusInd Bank, Sun Pharma, ONGC, Vedanta and Marico will be in focus as the companies will announce their third qua...
- Biocon shares zoom 4% as Jefferies upgrades to "hold" amid positive news inflow, sets Rs 400 targetBiocon share price: This upgrade reflects a more positive outlook on the company following recent favorable news flow, particularly concern...
- Biocon Biologics mulls raising up to Rs 4,500 crore in bondsThe company is in discussions with banks for the issuance, the people said, asking not to be named because the details are private. Funds f...
- Stocks in news: ZEE, M&M Financial, Dr Reddy's, Wipro, BioconDomestic markets rally on exit polls predicting Modi government's massive mandate. ZEE, M&M Financial, Dr Reddy's, Wipro, Biocon in focus. ...
- Biocon Biologics' Malaysia insulin facility classified by US FDA for official actionBiocon Biologics has announced that its insulin manufacturing facility in Johor, Malaysia has been classified as an official action indicat...
- Allegations 'serious' & 'grave', says special court in Biocon Biologics caseThe special CBI court, in an 80-page order rejecting the bail pleas of all five accused in the case earlier this week, said: "The questions...
- Biocon Biologics bribery case: Bail pleas of five accused rejectedThe CBI last month arrested Central Drugs Standard Control Organisation (CDSCO) joint drug controller S Eswara Reddy and Biocon Biologics h...
- Biocon Biologics denies bribery charge; says it follows due regulatory process for product approvalsThe CBI has arrested Joint Drugs Controller S Eswara Reddy, Associate Vice President of Biocon Biologics L Praveen Kumar and three others i...
- Biocon Biologics to file for IPO within next 2 years: Kiran Mazumdar-Shaw"And obviously, we expect the IPO to be at a very, very attractive level. So if you look at it, it's going to hugely create value for share...
- Biocon founder Kiran Mazumdar Shaw hails expert panel’s nod to Sputnik V“It adds to our armoury. I hope it is one more step towards vaccinating the general population,” Shaw told ET on hearing the news about a t...
- Biocon confident of accelerated growth in FY22: Kiran Mazumdar-ShawBiocon's Executive Chairperson Kiran Mazumdar-Shaw on the company’s plans for fresh capital infusion in Biocon Biologics, growth opportunit...
- Tata Capital picks up 0.85% stake in Biocon Biologics for $30 millionPost the completion of this transaction, Biocon will hold a 95.25 per cent stake in Biocon Biologics.
- Biosimilar drug by Mylan, Biocon gets USFDA approvalBiosimilar drugs are identical copy of highly complex biologic drugs that claim to have the same efficacy as that off the innovator’s versi...
- GE capital picks up 7.69% in Biocon's Syngene for Rs 125 croreThe total valuation of Syngene with this investment stands at Rs 1600 cr. Following the news, Biocon shares jumped by over 3%.
Load More
